



RNS Number : 8800P
Trellus Health PLC
23 June 2022

Trellus Health plc
("Trellus Health" or the "Company")

Trellus strengthens Board with appointment of Traci Entel as Non-Executive Director and Grant of Options

LONDON, U.K. AND NEW YORK, U.S. (23 June 2022). Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, resilience-based, connected health solution for chronic condition management, announces the appointment of Traci Entel as a Non-Executive Director, with immediate effect.

Traci has 22 years' experience in healthcare, technology, and financial services across high-growth and large organisations as a management consultant and global HR executive. She has been a member of multiple HR leadership teams and business operating committees and has significant expertise in leading teams and advising executives on HR strategies, culture, organisational effectiveness, diversity and inclusion policies, and implementing talent strategies.

Traci is currently a partner at Incandescent, a New York-based management consultancy firm, where she is focused on partnering with leaders to achieve their organization, culture, and talent objectives.

Previously, as the Head of Employee Experience at Stripe and Head of Talent Management at BlackRock, Traci led the firms' talent and culture strategies, including annual performance processes and career development, leadership development and succession, broader learning, people analytics, inclusion & diversity, and M&A. At BlackRock, she was also the lead HR Business Partner for the firm's non-investment functions including technology, operations, institutional sales, and corporate functions. As Chief Human Capital Officer at Booz & Company, Traci developed and delivered a business-back talent strategy and led the integration with PwC to create Strategy&.

Prior to Traci's 10 years in HR leadership roles, she worked in consulting for 14 years partnering with executives in healthcare, consumer products, and financial services. Starting her career at Mitchell Madison Group, she then spent 10 years with Katzenbach Partners, which was acquired by Booz & Company. At Booz & Company, Traci was a Partner in the firm's Organization, Change and Leadership, and Healthcare practices where she focused on culture evolution & behavior change, talent strategy, and frontline effectiveness. She later led the people and cultural integration of Booz & Company with PwC to form Strategy&.

Traci is a Partnership for New York City David Rockefeller Fellow and member of the

Women's Forum of New York.

Monique Fayad, CEO of Trellus Health, said: *"We are delighted to welcome Traci Entel to the Trellus Health Board. She brings significant experience in the creation and implementation of successful HR strategies across a number of organisations of varying size and in different fields. Her experience in organisational design, culture and talent management will be invaluable as we seek to attract and retain the best talent to support the rapid growth of the business, especially amidst a highly competitive hiring environment."*

Traci Allison Entel (aged 46) does not currently hold any directorships or partnerships and has not previously held any directorships or partnerships in the past five years.

The Company announces that Traci Entel has been granted options to subscribe for up to 100,000 ordinary shares of 0.06 pence each in the capital of the Company (the "Options"), at an exercise price of 40 pence per ordinary share, as part of her compensation. The Options are exercisable three years from the date of grant.

Traci Entel has no other holdings of ordinary shares or options in the Company.

Following this grant, the Company has 4,411,250 options in issue, representing 2.7 per cent of the Company's issued share capital.

Save as disclosed above, there is no further information to be disclosed in respect of the appointment, pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for companies.

For further information please contact:

Trellus Health plc
Monique Fayad, CEO
Julian Baines, Chairman

www.trellushealth.com
Via Walbrook PR

Singer Capital Markets (Nominated Adviser & Broker) Tel: 020 7496 3000
Aubrey Powell / Jen Boorer

Walbrook PR Limited
Paul McManus / Louis Ashe-Jepson

Tel: 020 7933 8780 or trellus@walbrookpr.com
Mob: 07980 541 893 / 07747 515 393

About Trellus Health plc (www.trellushealth.com)

Trellus Health (LSE: TRLS) is the first digital health company focused on the intersection of chronic physical conditions and mental health. Trellus Health integrates its proprietary resilience-based methodology with the technology, tools and team to deliver a whole-person technology-enhanced experience that results in relieving disease burden and promoting individual health behaviors that enable thriving in the face of a chronic condition. Through its TrellusElevate™ connected care platform and companion App, the company addresses both clinical and behavioral health together, in context, to improve outcomes and reduce healthcare costs for patients, employers, and the healthcare system.

The Company is initially focused on Inflammatory bowel disease ("IBD"), which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions, including Irritable Bowel Syndrome ("IBS").

The TrellusElevate™ platform is the Company's proprietary connected health platform that incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers. IBD patients treated using the methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following program completion (source: <https://www.sciencedirect.com/science/article/pii/S1542356521012258>).

The Company was founded by Mount Sinai faculty members Dr. Marla C. Dubinsky, MD and Dr. Laurie Keefer, PhD, both with decades of combined experience in IBD and psychogastroenterology, respectively. Trellus Health's patent-pending GRITT™ resilience assessment and personalized treatment methodology was developed and validated at the Mount Sinai Health System to build resilience and wellness for improved outcomes at lower cost.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit: www.trellushealth.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name Traci Entel

2 Reason for the notification

a) Position/status Non-Executive Director

b) Initial notification /Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name Trellus Health plc

b) LEI 2138002FHWJSR8YKP295

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument Options over ordinary shares of 0.06p each in Trellus Health plc

Identification code ISIN for Trellus Health plc ordinary shares GB00BNNFM402

b) Nature of the transaction Grant of options over ordinary shares

c)	Price(s) and volume(s)	Price(s)	Volume(s)
		40 pence	100,000
d)	Aggregated information - Aggregated volume - Price	N/A	
e)	Date of the transaction	22 June 2022	
f)	Place of the transaction	Outside a trading venue	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOADBGLRDDDGDGDD Anonymous (not verified) Directorate Change
<http://www.DigitalLook.com>
 32769327 A Thu, 06/23/2022 - 07:00 LSE RNS Executive Changes TRLS